Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label, Single-Arm Study of BGB-290 (BGB-290) for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) With Homologous Recombination Deficiency (HRD)

NCT03712930 is registered in ClinicalTrials.gov with BeiGene as lead sponsor.

NCT NCT03712930
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03712930 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label, Single-Arm Study of BGB-290 (BGB-290) for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) With Homologous Recombination Deficiency (HRD)
Lead sponsor
BeiGene
Phase
Phase 2
Overall status
Terminated
Start date
February 5, 2019
Completion date
September 2, 2020
Enrollment
13 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

homologous recombination deficiency (hrd), metastatic castration-resistant prostate cancer (mcrpc)